Elevation Oncology【ELEV】銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

0.608

買値

0.594

売値

0.6171

出来高

2,443,425

0.55 日の範囲 0.66

0.4401 52 週間の範囲 5.8299

時価総額

35.944M

前日終値

0.6257

始値

0.6339

時刻

2300

0.608

(formt)

最終取引時間

財務取引量

US$ 1,514,886

VWAP

0.619985

平均取引量 (3 か月)

712,859

発行済株式数

59,119,055

配当利回り

PER

-0.72

1 株当たり利益 (EPS)

-0.77

歳入

純利益

-45.7M

Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be th... Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition. 詳細を表示

セクター

Biological Pds,ex Diagnstics

業界

Biological Pds,ex Diagnstics

ウェブサイト

www.elevationoncology.com

本社

Camden, Delaware, USA

設立

Elevation Oncology Inc is listed in the Biological Pds,ex Diagnstics sector of the ナスダック市場 with ticker ELEV. The last closing price for Elevation Oncology was US$0.63. Over the last year, Elevation Oncology shares have traded in a share price range of US$ 0.4401 to US$ 5.8299.

Elevation Oncology currently has 59,119,055 shares in issue. The market capitalisation of Elevation Oncology is US$36.99 million. Elevation Oncology has a price to earnings ratio (PE ratio) of -0.72.

Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors

Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors PR Newswire BOSTON, Dec. 12, 2024 -- EO-1022 is comprised of...

Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024

Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024 PR...

Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2

Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing...

Form 8-K - Current report

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.0634	-9.44295501936	0.6714	0.7	0.56	764090	0.63961148	CS
4	-0.0022	-0.360537528679	0.6102	0.8099	0.56	743935	0.65001628	CS
12	0.0326	5.6656239138	0.5754	0.8099	0.5	712859	0.60291768	CS
26	-2.172	-78.1294964029	2.78	3.28	0.5	970479	1.07352699	CS
52	0.098	19.2156862745	0.51	5.8299	0.4401	1409199	2.1643119	CS
156	-3.762	-86.0869565217	4.37	6.866	0.363	779867	2.55795074	CS
260	-13.392	-95.6571428571	14	16.22	0.363	680779	2.66232168	CS

ELEV - Frequently Asked Questions (FAQ)

What is the current Elevation Oncology share price?

The current share price of Elevation Oncology is US$ 0.608

How many Elevation Oncology shares are in issue?

Elevation Oncology has 59,119,055 shares in issue

What is the market cap of Elevation Oncology?

The market capitalisation of Elevation Oncology is USD 36.99M

What is the 1 year trading range for Elevation Oncology share price?

Elevation Oncology has traded in the range of US$ 0.4401 to US$ 5.8299 during the past year

What is the PE ratio of Elevation Oncology?

The price to earnings ratio of Elevation Oncology is -0.72

What is the reporting currency for Elevation Oncology?

Elevation Oncology reports financial results in USD

What is the latest annual profit for Elevation Oncology?

The latest annual profit of Elevation Oncology is USD -45.7M

What is the registered address of Elevation Oncology?

The registered address for Elevation Oncology is 2140 S DUPONT HWY, KENT, CAMDEN, DELAWARE, 19934

What is the Elevation Oncology website address?

The website address for Elevation Oncology is www.elevationoncology.com

Which industry sector does Elevation Oncology operate in?

Elevation Oncology operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

銘柄コード	株価	出来高
MYSZMy Size Inc	US$ 4.2001 (211.12%)	121.03M
NVNINVNI Group Ltd	US$ 8.26 (209.36%)	78.06M
TPICTPI Composites Inc	US$ 2.45 (100.82%)	34M
ICGIntchains Group Ltd	US$ 8.77 (88.60%)	527.94k
HSDTHelius Medical Technologies Inc	US$ 0.884851 (84.34%)	121.95M
CYNCYNGN Inc	US$ 0.4603 (-71.41%)	27.5M
MTEMMolecular Templates Inc	US$ 0.1502 (-57.09%)	8.63M
PRFXPainReform Ltd	US$ 5.15 (-53.85%)	2.84M
GALTGalectin Therapeutics Inc	US$ 1.03 (-48.50%)	8.58M
BCABBioAtla Inc	US$ 0.6923 (-41.82%)	5.96M
EDBLEdible Garden AG Inc	US$ 0.24 (65.06%)	354.33M
NVDANVIDIA Corporation	US$ 134.70 (3.08%)	310.19M
APTOAptose Biosciences Inc	US$ 0.28 (64.51%)	306.25M
TNXPTonix Pharmaceuticals Holding Corporation	US$ 0.606999 (6.49%)	293.22M
PLTRPalantir Technologies Inc	US$ 80.55 (8.54%)	281.23M

銘柄コード

株価

出来高